Jenkins John Kenneth
SEC Form 4 insider trading activity
Jenkins John Kenneth has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 11, 2026.
On the most recent filing, Jenkins John Kenneth is listed as Director at Corbus Pharmaceuticals Holdings, Inc. Inside the rolling window, Jenkins John Kenneth reported no open-market purchases and 1 open-market sale totaling $38K in CRBP.
Companies traded
Other insiders at CRBP
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$38K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Jenkins John Kenneth made?
Jenkins John Kenneth has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does Jenkins John Kenneth trade?
Jenkins John Kenneth has filed SEC Form 4 disclosures for 1 company, including CRBP.
When was Jenkins John Kenneth's most recent SEC Form 4 filing?
Jenkins John Kenneth's most recent SEC Form 4 filing on Tracefour is dated Jun 11, 2026.
What is Jenkins John Kenneth's total buy and sell value in the current window?
Inside the rolling retention window, Jenkins John Kenneth bought $0 and sold $38K based on SEC Form 4 filings.
What was Jenkins John Kenneth's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 4,800 CRBP shares on 2026-06-10, worth $38K, per SEC Form 4 filings.